Literature DB >> 23453870

Review of epidemiology and management of atrial fibrillation in developing countries.

Tu N Nguyen1, Sarah N Hilmer, Robert G Cumming.   

Abstract

BACKGROUND: Atrial fibrillation (AF) is the commonest sustained cardiac arrhythmia. In developing countries, AF is a growing public health problem with the epidemiologic transition from communicable to non-communicable diseases. However, relatively little is known about AF in the developing world. The aim of this review is to examine in developing countries the prevalence, associated medical conditions and management of AF.
METHODS: A literature search was conducted via MEDLINE and EMBASE (1990-2012).
RESULTS: Seventy studies were included in the review. The prevalence of AF in the general population ranged from 0.03% to 1.25%, while the prevalence of AF in hospital-based studies varied from 0.7% to 55.7%. Prevalence of AF in Africa was lower than in other regions. The most common conditions associated with AF were hypertension (10.3%-71.9%) and valvular heart disease (5.6%-66.3%). The prevalence of stroke in patients with AF ranged from 6.7% to 27%. The utilization of anticoagulants was highly variable (2.7%-72.7%). Approximately half of the patients with AF using warfarin had therapeutic International Normalized Ratios (INR). There was a high prevalence of use of rate control therapies (55.3%-87.3%).
CONCLUSIONS: The limited studies available suggest that in the developing world there is a significant prevalence of AF, which is predominantly associated with hypertension and valvular heart disease, and carries a risk of stroke. Highly variable use of anticoagulants may be related to different health care and socioeconomic settings. More studies are needed to improve understanding of the epidemiology and management of AF in developing countries.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Antithrombotic therapies; Atrial fibrillation; Developing countries

Mesh:

Substances:

Year:  2013        PMID: 23453870     DOI: 10.1016/j.ijcard.2013.01.184

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  33 in total

1.  Atrial fibrillation in organ transplant recipients: only a marker of the underlying disease?

Authors:  Francesca Innocenti; Riccardo Pini
Journal:  Intern Emerg Med       Date:  2018-11-29       Impact factor: 3.397

2.  Atrial fibrillation: prevalence in a large database of primary care patients in Brazil.

Authors:  Milena S Marcolino; Daniel M F Palhares; Emelia J Benjamin; Antonio L Ribeiro
Journal:  Europace       Date:  2015-06-07       Impact factor: 5.214

3.  Impact of Pulmonary Vein Anatomy on Long-term Outcome of Cryoballoon Ablation for Atrial Fibrillation.

Authors:  Shang-Wei Huang; Qi Jin; Ning Zhang; Tian-You Ling; Wen-Qi Pan; Chang-Jian Lin; Qing-Zhi Luo; Yan-Xin Han; Li-Qun Wu
Journal:  Curr Med Sci       Date:  2018-04-30

Review 4.  Potential use of NOACs in developing countries: pros and cons.

Authors:  Durga Bista; Leanne Chalmers; Luke Bereznicki; Gregory Peterson
Journal:  Eur J Clin Pharmacol       Date:  2014-05-11       Impact factor: 2.953

5.  Rationale and design of VENTURE-AF: a randomized, open-label, active-controlled multicenter study to evaluate the safety of rivaroxaban and vitamin K antagonists in subjects undergoing catheter ablation for atrial fibrillation.

Authors:  Gerald V Naccarelli; Riccardo Cappato; Stefan H Hohnloser; Francis E Marchlinski; David J Wilber; Jim Xiang; Changsheng Ma; Susanne Hess; David Wyn Davies; Larry E Fields; Andrea Natale
Journal:  J Interv Card Electrophysiol       Date:  2014-07-09       Impact factor: 1.900

Review 6.  The Optimal Treatment For Atrial Fibrillation In Less Developed Countries.

Authors:  Xiaohan Fan; Shu Zhang
Journal:  J Atr Fibrillation       Date:  2014-10-31

7.  Effect of Evidence-Based Pharmacy Care on Satisfaction and Cognition in Patients with Non-Valvular Atrial Fibrillation Taking Rivaroxaban.

Authors:  Jie Sun; Guo-Mei Chen; Ji Huang
Journal:  Patient Prefer Adherence       Date:  2021-07-25       Impact factor: 2.711

Review 8.  Atrial fibrillation in Sub-Saharan Africa: epidemiology, unmet needs, and treatment options.

Authors:  Bruce Sheldon Stambler; Leonard M Ngunga
Journal:  Int J Gen Med       Date:  2015-07-31

9.  Young professionals for health development: the Kenyan experience in combating non-communicable diseases.

Authors:  Duncan M Matheka; Joseph Nderitu; Rajesh Vedanthan; Alessandro R Demaio; Mellany Murgor; Kiti Kajana; Poonamjeet Loyal; Faraj O Alkizim; Sandeep P Kishore
Journal:  Glob Health Action       Date:  2013-11-20       Impact factor: 2.640

10.  Atrial fibrillation in patients with SARS-CoV-2 infection.

Authors:  Pablo Elpidio García-Granja; Carlos Veras; Álvaro Aparisi; Ignacio J Amat-Santos; Pablo Catalá; Marta Marcos; Gonzalo Cabezón; Jordi Candela; José Francisco Gil; Aitor Uribarri; Ana Revilla; Manuel Carrasco; Itziar Gómez; José Alberto San Román
Journal:  Med Clin (Engl Ed)       Date:  2021-07-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.